AGI Therapeutics plc – Product Pipeline Review – H2 2011

Date: November 1, 2011
Pages: 43
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A0A25AF0D34EN
Leaflet:

Download PDF Leaflet

AGI Therapeutics plc – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “AGI Therapeutics plc - Product Pipeline Review - H2 2011” provides data on the AGI Therapeutics plc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, AGI Therapeutics plc’s corporate website, SEC filings, investor presentations and featured press releases, both from AGI Therapeutics plc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • AGI Therapeutics plc - Brief AGI Therapeutics plc overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of AGI Therapeutics plc human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of AGI Therapeutics plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the AGI Therapeutics plc’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate AGI Therapeutics plc’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of AGI Therapeutics plc in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the AGI Therapeutics plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with AGI Therapeutics plc.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of AGI Therapeutics plc and identify potential opportunities in those areas.
AGI Therapeutics plc Snapshot
AGI Therapeutics plc Overview
Key Information
Key Facts
AGI Therapeutics plc – Research and Development Overview
Key Therapeutic Areas
AGI Therapeutics plc – Pipeline Review
Pipeline Products by Stage of Development
AGI Therapeutics plc – Pipeline Products Glance
AGI Therapeutics plc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
AGI Therapeutics plc – Drug Profiles
AGI-004
  Product Description
  Mechanism of Action
  R&D Progress
AGI-006
  Product Description
  Mechanism of Action
  R&D Progress
AGI-022
  Product Description
  Mechanism of Action
  R&D Progress
AGI Therapeutics plc – Pipeline Analysis
AGI Therapeutics plc – Pipeline Products by Therapeutic Class
AGI Therapeutics plc - Pipeline Products By Target
AGI Therapeutics plc – Pipeline Products by Route of Administration
AGI Therapeutics plc – Pipeline Products by Molecule Type
AGI Therapeutics plc - Dormant Projects
AGI Therapeutics plc - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
AGI-001
AGI Therapeutics plc – Company Statement
AGI Therapeutics plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 29, 2006: AGI Therapeutics Announces Preliminary Results Of Phase II Trial Of Espindolol (AGI-001) In Irritable Bowel Syndrome
Mar 29, 2006: AGI Therapeutics plc Reports Results Of Clinical Studies For Product Candidate, AGI-010
Mar 29, 2006: AGI Therapeutics plc Reports Results Of Clinical Studies For Two Product Candidates
Sep 27, 2006: AGI Therapeutics plc Signs $19 million Exclusive License Agreement With Axcan Pharma For Delayed/Controlled Release Omeprazole, AGI-010
Feb 21, 2008: Clinical Study Supports The Pharmacokinetic And Safety Profile Of Rezular
Mar 17, 2008: AGI Therapeutics Announces Completion Of The Optimisation Phase Of Development Of AGI-010
Aug 14, 2009: AGI Announces Termination Of Agreement With Axcan for AGI-010
Sep 12, 2007: FDA Accepts IND Filing For Arverapamil (AGI-003) Phase III programme
Mar 12, 2009: AGI Announces Positive Results In A Phase II Proof Of Concept Study Of AGI-004 In Chemotherapy-Induced Diarrhoea
Apr 11, 2007: AGI Therapeutics Plc FDA Approval To File IND For Arverapamil Phase III Study
Jun 07, 2006: AGI Therapeutics Announces Preliminary Results Of Phase II Trials For Gastrointestinal Disorders
Feb 05, 2008: AGI Announces First Patient Dosed In Phase II Trial Of AGI-004 In Chemotherapy-Induced Diarrhoea
Apr 02, 2008: AGI Announces Key Findings Of Clinical PK Study Of Arbaclofen (AGI-006)
Feb 01, 2007: AGI Therapeutics Announces Preliminary Clinical Data For Phase II Trials Of AGI-006
Financial Deals Landscape
AGI Therapeutics plc, Deals Summary
AGI Therapeutics plc, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
AGI Therapeutics Acquires IP Rights From Athpharma
Venture Financing
AGI Therapeutics Raises $11.3 Million In Series A Financing
Licensing Agreements
AGI Therapeutics Enters Into Licensing Agreement With Axcan Pharma
Equity Offering
AGI Therapeutics Completes IPO For $50 Million
Asset Transactions
Warner Chilcott Acquires Patent And Intellectual Property Rights From AGI Therapeutics
Acquisition
AGI Therapeutics Acquires AGI Therapeutics Research
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

AGI Therapeutics plc – Pipeline by Therapy Area and Indication, H2 2011
AGI Therapeutics plc – Pipeline by Stage of Development, H2 2011
AGI Therapeutics plc - Phase II, H2 2011
AGI Therapeutics plc - Pipeline By Therapeutic Class, H2 2011
AGI Therapeutics plc - Pipeline By Target, H2 2011
AGI Therapeutics plc – Pipeline By Route of Administration, H2 2011
AGI Therapeutics plc – Pipeline By Molecule Type, H2 2011
AGI Therapeutics plc - Dormant Developmental Projects, 2010
AGI Therapeutics plc - Discontinued Pipeline Products, 2010
AGI Therapeutics plc, Subsidiaries
AGI Therapeutics plc, Deals Summary
AGI Therapeutics Acquires IP Rights From Athpharma
AGI Therapeutics Raises $11.3 Million In Series A Financing
AGI Therapeutics Enters Into Licensing Agreement With Axcan Pharma
AGI Therapeutics Completes IPO For $50 Million
Warner Chilcott Acquires Patent And Intellectual Property Rights From AGI Therapeutics
AGI Therapeutics Acquires AGI Therapeutics Research

LIST OF FIGURES

AGI Therapeutics plc – Pipeline by Therapy Area and Indication, H2 2011
AGI Therapeutics plc – Pipeline by Stage of Development, H2 2011
AGI Therapeutics plc – Pipeline By Therapeutic Class, H2 2011
AGI Therapeutics plc - Pipeline By Target, H2 2011
AGI Therapeutics plc – Pipeline By Route of Administration, H2 2011

Ask Your Question

AGI Therapeutics plc – Product Pipeline Review – H2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: